BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8831997)

  • 1. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
    Wong EK; Eaves C; Klingemann HG
    Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
    Klingemann HG; Deal H; Reid D; Eaves CJ
    Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
    Klingemann HG; Wong E; Maki G
    Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points.
    Verma UN; Mazumder A
    Bone Marrow Transplant; 1995 Sep; 16(3):365-72. PubMed ID: 8535308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to purging of leukemia by activation of bone marrow with interleukin 2.
    Charak BS; Malloy B; Agah R; Mazumder A
    Bone Marrow Transplant; 1990 Sep; 6(3):193-8. PubMed ID: 2252959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
    Verma UN; Bagg A; Brown E; Mazumder A
    Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
    Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
    Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costimulatory signals are required for optimal proliferation of human natural killer cells.
    Robertson MJ; Manley TJ; Donahue C; Levine H; Ritz J
    J Immunol; 1993 Mar; 150(5):1705-14. PubMed ID: 7679691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.
    Miller JS; Tessmer-Tuck J; Blake N; Lund J; Scott A; Blazar BR; Orchard PJ
    Exp Hematol; 1997 Oct; 25(11):1140-8. PubMed ID: 9328450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer (NK) cell activity in human long-term bone marrow cultures (LTBMC): effects of interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on the progenitor cells.
    Sitnicka E; Hansson M
    Immunology; 1992 Jun; 76(2):292-8. PubMed ID: 1634251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
    Condiotti R; Nagler A
    Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
    Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
    Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on the antitumor activity of CBMC activated by IL-12 alone or in combination with IL-2].
    Xia D; Wang J; Shao C; Shen J; Bao J
    Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):30-3. PubMed ID: 11876958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rIL-7 on murine bone marrow NK precursor cells.
    Pollack SB; Tsuji J
    Cell Immunol; 1993 Oct; 151(1):1-11. PubMed ID: 8402921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.
    Robertson MJ; Cameron C; Lazo S; Cochran KJ; Voss SD; Ritz J
    Nat Immun; 1996-1997; 15(5):213-26. PubMed ID: 9390270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18.
    Lauwerys BR; Renauld JC; Houssiau FA
    Cytokine; 1999 Nov; 11(11):822-30. PubMed ID: 10547269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.